Department of Microbiology and Immunology, Jeju National University School of Medicine, Jeju, Korea.
Int J Tuberc Lung Dis. 2012 Jan;16(1):98-103. doi: 10.5588/ijtld.10.0739.
Pyrazinamide (PZA), one of the most effective anti-tuberculosis drugs, becomes toxic to Mycobacterium tuberculosis when converted to pyrazinoic acid by pyrazinamidase (PZase). PZA resistance is caused mainly by the loss of enzyme activity by mutation.
To investigate the patterns of pncA mutations in PZA-resistant mycobacteria isolated from South Korean patients.
Mycobacterial isolates with clinically proven drug resistance were cultured to determine susceptibility to anti-tuberculosis agents. pncA mutations were recognised by sequencing and compared with the relevant wild-type DNA sequence.
Among 108 isolates, 102 were successfully cultured and underwent drug susceptibility testing; all were multidrug-resistant (MDR). pncA mutations were found in 86 cultured isolates (85.1%): 55 (84.6%) in MDR and 31 (86.1%) in extensively drug-resistant isolates. Substitution of a single nucleotide was most common. The most frequent mutations were a deletion that caused a frameshift at nucleotide (nt) 71, a substitution at nt 403 and a substitution at nt 11. Combined, these accounted for ≈ 40% of all mutations. However, 15 samples (14.9%) with defective PZase activity showed no mutation.
pncA mutation in M. tuberculosis is a major mechanism of PZA resistance in MDR isolates from patients in South Korea. The patterns of mutation might be more scattered and diverse. DNA-based diagnosis of PZA resistance has potential for the rapid detection of drug resistance.
吡嗪酰胺(PZA)是最有效的抗结核药物之一,当被吡嗪酰胺酶(PZase)转化为吡嗪酸时,它对结核分枝杆菌变得有毒。PZA 耐药主要是由于突变导致酶活性丧失。
研究韩国患者分离的耐吡嗪酰胺分枝杆菌中 pncA 突变的模式。
培养具有临床证实耐药性的分枝杆菌分离物,以确定对抗结核药物的敏感性。通过测序识别 pncA 突变,并与相关的野生型 DNA 序列进行比较。
在 108 株分离物中,成功培养了 102 株并进行了药敏试验;均为耐多药(MDR)。在 86 株培养的分离物中发现了 pncA 突变(85.1%):55 株(84.6%)在 MDR 中,31 株(86.1%)在广泛耐药分离物中。单核苷酸取代最常见。最常见的突变是核苷酸(nt)71 处的移码缺失、nt403 的取代和 nt11 的取代。这些突变加起来约占所有突变的 40%。然而,15 个(14.9%)具有缺陷 PZase 活性的样本没有突变。
结核分枝杆菌中 pncA 突变是韩国患者 MDR 分离物中 PZA 耐药的主要机制。突变模式可能更加分散和多样化。基于 DNA 的 PZA 耐药性诊断具有快速检测耐药性的潜力。